New Biden Executive Order Targets Hospital Mergers & Drug Pricing, Renews Antitrust Focus

Last week, the Biden Administration unveiled a sweeping executive
order, focused on promoting competition in the US economy.


With Lina Khan as the new chairperson of the Federal Trade
Commission, the administration is looking to increase its
antitrust focus and potentially break up monopolies.


The new executive order contains 72 provisions, giving direction
to multiple agencies on sectors such as agriculture,
transportation, labor, and health care. In health care, the
executive order focuses on drug pricing, hospital mergers and
acquisitions, hospital pricing transparency, biosimilars, and
comparison shopping for health plans.


Listen to Health Affairs' Deputy Editor Rob Lott and Senior
Content Marketing Manager Jeff Byers go over the health care
sections in the Biden administration's executive order on
promoting competition in the US economy. They also discuss the
hipster antitrust movement, the cost of hearing aids, and
hospital deal trends since the implementation of the Affordable
Care Act.


Related Links:


Fact Sheet: Executive Order On Promoting Competition In The
American Economy (White House)

Hospital M&A Down From Pre-Pandemic Highs, Though Deal
Size Growing, Kaufman Hall Says (Healthcare Dive)

Biden Administration's First Marketplace Rule Promotes
Coverage and Reverse Trump-Era Changes (Health Affairs Blog)

How Biosimilars Are Affecting The Drug Markets (A Health
Podyssey)

Lina Khan And the "Hipster Antitrust" Movement (The Atlantic)

The End of Friedmanomics (The New Republic)




Subscribe: RSS | Apple Podcasts | Spotify | Castro | Stitcher |
Deezer | Overcast